

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Weshington, D.C. 20231
www.uspto.gov

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	09/465,444	12/16/1999	HENRY W. FOUNDS	361331-009RE	8872
	7	7590 12/07/2001		•	
	THOMAS S DEIBERT DECHERT PRICE & RHOADS PRINCETON PIKE CORPORATE CENTER			EXAMINER	
				NOLAN, PATRICK J	
	POBOX 5218		· · · · · · · · · · · · · · · · · · ·		
		NJ 085435218		ART UNIT	PAPER NUMBER
				1644	10
				DATE MAILED: 12/07/2001	ω

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

Applicant(s)

09/465,444

Founds et al.

Examiner

Patrick J. Nolan

Art Unit 1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). **Status** 1) Responsive to communication(s) filed on Aug 27, 2001 2a) This action is FINAL. 2b) X This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-9 and 11-16 is/are pending in the application. 4a) Of the above, claim(s) ______ is/are withdrawn from consideratio 5) ☐ Claim(s) ______is/are allowed. 6) X Claim(s) <u>1-9 and 11-16</u> is/are rejected. 7) Claim(s) ______ is/are objected to. 8) Claims are subject to restriction and/or election requirement **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are objected to by the Examiner. 11) The proposed drawing correction filed on is: all approved by disapproved. 12) \square The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) ☐ All b) ☐ Some* c) ☐ None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 20) Other:

Serial Number: 09/465,444 Page 2

Art Unit: 1644

j = '

DETAILED ACTION

1. This application is a Reissue application of U.S. Patent 5,698,197.

- 2. Claims 1-9 and 11-16 are pending.
- 3. It is noted that the Deposit certificate and declaratory assurances Faxed to the Examiner on Nov. 16, 2001 has been entered into the case.
- 4. In view of the Appeal Brief filed on 8-27-01, PROSECUTION IS HEREBY REOPENED. A new ground of ejection is set forth below.

To avoid abandonment of the application, appellant must exercise one of the following two options:

- (a) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37 CFR 1.113 (if this Office action is final); or,
- (b) request reinstatement of the appeal.

If reinstatement of the appeal is requested, such request must be accompanied by a supplemental appeal brief, but no new amendments, affidavits (37 CFR 1.130, 1.131 or 1.132) or other evidence are permitted. See 37 CFR 1.193(b)(2).

- 5. The specification on page 1 should be amended to reflect the status of the parent application, serial number 08/367,507, now U.S. Patent 5,744,318.
- 6. The original patent, or an affidavit or declaration as to loss or inaccessibility of the original patent, must be received before this reissue application can be allowed. See 37 CFR 1.178.
- 6. The reissue oath/declaration filed with this application is defective because it fails to contain the statement required under 37 CFR 1.175(a)(1) as to applicant's belief that the original patent is wholly or partly inoperative or invalid. See 37 CFR 1.175(a)(1) and see MPEP § 1414.

The reissue oath/declaration filed with this application is defective because it fails to identify at least one error which is relied upon to support the reissue application. See 37 CFR 1.175(a)(1) and MPEP § 1414.

In accordance with 37 CFR 1.175(b)(1), a supplemental reissue oath/declaration under 37 CFR 1.175(b)(1) must be received before this reissue application can be allowed.

Claims 1-9 and 11-16 are rejected as being based upon a defective declaration under 35 U.S.C. 251. See 37 CFR 1.175. The nature of the defect is set forth above.

Serial Number: 09/465,444 Page 3

Art Unit: 1644

Receipt of an appropriate supplemental oath/declaration under 37 CFR 1.175(b)(1) will overcome this rejection under 35 U.S.C. 251. An example of acceptable language to be used in the supplemental oath/declaration is as follows:

"Every error in the patent which was corrected in the present reissue application, and is not covered by a prior oath/declaration submitted in this application, arose without any deceptive intention on the part of the applicant."

Claims 9 and 11-16 are rejected under 35 U.S.C. 251 as being improper recapture of broadened claimed subject surrendered in the application for the patent upon which the present reissue is based. See Hester Industries, Inc. v. Stein, Inc., 142 F.3d 1472, 46 USPQ2d 1641 (Fed. Cir. 1998); In re Clement, 131 F.3d 1464, 45 USPQ2d 1161 (Fed. Cir. 1997); Ball Corp. v. United States, 729 F.2d 1429, 1436, 221 USPQ 289, 295 (Fed. Cir. 1984). A broadening aspect is present in the reissue which was not present in the application for patent. The record of the application for the patent shows that the broadening aspect (in the relates to subject matter that applicant previously surrendered during the prosecution of the application. Accordingly, the narrow scope of the claims in the patent was not an error within the meaning of 35 U.S.C. 251, and the broader scope surrendered in the application for the patent cannot be recaptured by the filing of the present reissue application.

In parent case 08/483,186, Applicant surrendered subject drawn to "immunological binding characteristic of monoclonal antibody 4G9" in the Interview Summary dated 5/27/97, which resulted in the issuing of claims drawn to a single deposited monoclonal antibody 4G9. In the reissue case claims drawn to a monoclonal antibody that matches 6 amino-caproic antigen binding of reference monoclonal antibody 4G9, broadens the claims that relates to subject matter that applicant previously surrendered during the prosecution of the parent Application. Both the surrendered subject matter of the parent case and the instant claims of the reissue are drawn to genus claims using binding characteristics of the deposited 4G9 monoclonal as reference points.

- 8. Claim 3 is objected to because of the following informalities: Chimeric is misspelled. Appropriate correction is required.
- 9. Applicant is kindly requested to supply a PTO-1449 citing all of the references cited on the face of the issued patent.
- 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick

Serial Number: 09/465,444

Art Unit: 1644

Nolan whose telephone number is (703) 305-1987. The examiner can normally be reached on Monday through Friday from 8:30 am to 4:30 pm.

Page 4

11. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at (703) 305-3973. The FAX number for our group, 1644, is (703) 305-7939. Any inquiry of a general nature relating to the status of this application or proceeding should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Patrick J. Nolan, Ph.D.

Primary Examiner, Group 1640

December 6, 2001